Liqitomic is a UK-developed on-site anatomical waste disposal technology that replaces high-temperature incineration with a chemical dissolution process — neutralizing human and animal tissue, bone, and skin in under one hour. Developed by Sanondaf, a UK decontamination specialist operating since 2014, Liqitomic targets a global clinical waste market still dominated by carbon-heavy incinerators and centralized hauling fleets.
For franchise investors, Liqitomic is unusual: a services concept whose defensibility comes from scientific validation rather than brand recognition, with a minimum investment requirement of US$250,000.
Liqitomic is a next-generation anatomical waste treatment system that uses chemical dissolution to safely break down human and animal tissue at the point of generation — hospitals, veterinary clinics, biomedical research labs, and field operations. The technology is owned and developed by Sanondaf, the UK group already franchising advanced infection-control services across multiple territories.
Unlike conventional incinerators, which require centralized facilities, refrigerated transport, and emit airborne pollutants, Liqitomic units are compact, portable, and installed on-site. A single cycle typically completes in under 60 minutes, neutralizing waste for standard discharge.
The clinical waste industry has resisted innovation for two reasons: regulatory caution and capital intensity. Liqitomic breaks both barriers.
The chemistry itself sits in the well-established alkaline hydrolysis family — a category already permitted in funeral services and pathology disposal across multiple jurisdictions. What’s new is the form factor: a compact unit small enough to install inside a hospital basement or veterinary clinic, removing the cold chain and the haul to a centralized incinerator.
The environmental case is also concrete. Incineration of anatomical waste releases particulates, dioxins, and significant CO₂. Liqitomic eliminates the emissions, the freezing step, and the transport mileage in a single intervention — which matches the way GapMaps and other modern B2B franchises position themselves: science-led, data-defensible, and aligned with ESG procurement.
The system was subjected to an 18-month independent validation project at a UK university and proven across commercial operations. That body of evidence — rather than marketing — is what franchisees use when selling into hospital procurement teams, which typically require peer-reviewed performance data before signing a service contract.
| Dimension | Traditional Incineration | Liqitomic |
|---|---|---|
| Location | Centralized facility | On-site at hospital / lab |
| Processing Time | Multi-day cycle including transport | Under 1 hour |
| Transport & Cold Chain | Required | Eliminated |
| Emissions | Particulates, dioxins, CO₂ | Minimal |
| Manual Handling Risk | High | Low — closed system |
The most natural early markets are jurisdictions where (a) clinical waste regulation is tightening, (b) hospitals are under cost pressure, and (c) ESG reporting is becoming mandatory. That description fits much of the GCC, Singapore, Hong Kong, Malaysia, and Vietnam — the same MENA and Asia Pacific corridors where infection-control services have already scaled.
Veterinary clinics and biomedical research universities form a second adjacent vertical that traditional clinical-waste vendors underserve.
Liqitomic is a UK-developed chemical dissolution system for anatomical waste disposal — neutralizing tissue, bone, and skin on-site in under one hour, replacing traditional incineration.
Liqitomic was developed by Sanondaf, a UK-based decontamination and infection-control specialist operating since 2014. The technology was validated through an 18-month scientific trial at a leading UK university.
The minimum investment required is US$250,000, as listed on the VF Franchise Consulting brand page for Liqitomic.
Liqitomic is one of the few franchise propositions where the moat is laboratory data rather than logo recognition. For master franchise investors with healthcare procurement relationships — or operators already running infection-control routes — the technology converts a heavily regulated, slow-moving disposal market into an on-site service line with measurable ESG and cost-saving outcomes. The combination of compact unit format, scientific validation, and a defined US$250,000 entry point makes it a credible adjacency for any healthcare-services portfolio in Asia and MENA.
This article was prepared by the VF Franchise Consulting editorial team — with over 30 years of experience in international franchise development, master franchise advisory, and brand expansion across Asia and the Middle East.
